Lupin, India’s fourth-largest drug-maker by sales is planning to launch three-four new generic drugs in its key US market by end of FY13. So far, the company has launched six products in this fiscal in the United States, which generates about 42% of its total formulation sales.
The drug-maker earlier reported a forecast-beating 42.6% rise in quarterly net profit to Rs 335 crore.
The company, on consolidated basis, reported 42.61% rise in its net profit at Rs 335.23 crore for the quarter ended December 31, 2012 as compared to Rs 235.06 crore for the same quarter in the previous year. Total income of the company increased by 38.71% at Rs 2527.57 crore for quarter under review as compared to Rs 1822.24 crore for the quarter ended December 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1874.30 |
| Dr. Reddys Labs. | 1327.00 |
| Cipla | 1437.80 |
| Zydus Lifesciences | 1100.45 |
| Lupin | 2366.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: